SGLT2 Inhibitors Reduce Sudden Cardiac Death Risk in Heart Failure: Meta-analysis of Randomized Clinical Trials.
Connor P OatesCarlos G Santos-GallegoAlex SmithBinaya BasyalNoah MossIwanari KawamuraDaniel R MusikantowMohit K TuragamMarc A MillerWilliam WhangSrinivas R DukkipatiVivek Y ReddyJacob S KoruthPublished in: Journal of cardiovascular electrophysiology (2023)
SGLT2i therapy is associated with a reduced risk of SCD in patients with heart failure receiving contemporary medical therapy. Prospective trials are needed to determine the long-term impact of SGLT2i therapy on atrial and ventricular arrhythmias. This article is protected by copyright. All rights reserved.